- Home
- PBAM vs SCTX Comparison
PBAM vs SCTX Comparison
Compare PBAM & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBAM | SCTX |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.7M | 536.5M |
| IPO Year | 2017 | 2026 |
Fundamental Metrics
Financial Performance| Metric | PBAM | SCTX |
|---|---|---|
| Price | $85.43 | $19.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $96.50 | $57.00 |
| AVG Volume (30 Days) | 119.5K | ★ 389.0K |
| Earning Date | 10-21-2026 | 09-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.34 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $11.69 | N/A |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $19.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $83.50 | $13.50 |
| 52 Week High | $92.09 | $39.60 |
Technical Indicators
Market Signals| Indicator | PBAM | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.30 | 39.85 |
| Support Level | $84.66 | $19.09 |
| Resistance Level | $87.15 | $26.50 |
| Average True Range (ATR) | 1.68 | 3.58 |
| MACD | -0.23 | -0.90 |
| Stochastic Oscillator | 30.07 | 26.07 |
Price Performance
Historical ComparisonAbout PBAM Private Bancorp of America Inc. Common Stock
Private Bancorp of America Inc is a commercial bank chartered by the State of California. It provides comprehensive banking services, including deposit accounts, treasury management services, and lending solutions tailored to high-net-worth individuals, professionals, family offices, closely-held businesses, real estate entrepreneurs, and small to mid-sized businesses. Lending activities include commercial real estate loans, commercial and industrial loans, and government-guaranteed lending programs.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.